ImmunoCellular +13.2%, wins orphan drug status for ICT-107 in the EU

ImmunoCellular Therapeutics (IMUC +13.2%) says it has been granted orphan drug designation for ICT-107 for the treatment of patients with glioblastoma.

Granting of orphan drug status in the EU provides sponsor companies with incentives, including a 10-year period of market exclusivity, access to a centralized review process, trial design assistance and scientific advice during product development, fee reductions, and tax incentives.

IMUC already had received orphan designation for ICT-107 in glioblastoma in the U.S.

Comments (4)
  • tinsley09
    , contributor
    Comments (339) | Send Message
    It appears that NWBO also was previously given orphan drug status in both the US and European Union.
    Hence the uninformed rhetoric from the Street,and the rapidly withdrawn article from Forbes, that DENDRITIC cell based immunotherapy is a primitive and dead is a bit premature.
    The science indicates that immunotherapy and specifically dendritic cells provide the best potential for an actual "cure "for cancer. Simply because dendritic cells can theoretically activate a wider range of immune system cells to kill tumors than any other known mechanisms to date.
    25 Feb 2014, 01:18 PM Reply Like
  • mikelazar
    , contributor
    Comments (434) | Send Message
    Their is a cure for everything right here on Earth it's just a matter of discovery.Stem cells hold the greatest promise for these discovery's. I Think stem cell therapy will be the drug of the future for a lot of diseases.Thats why i bought IMUC.
    25 Feb 2014, 09:20 PM Reply Like
  • opar
    , contributor
    Comments (55) | Send Message
    Thats right mikelazar!!....stem cell and Immunotherapy are the next generation of treatment. Johnson & Johnson scouted capricor for years and bought them out. J&J team are working with bioheart too.
    30 Mar 2014, 03:10 AM Reply Like
  • barrissimo
    , contributor
    Comment (1) | Send Message
    retired head concierege of condo--active investor in emerging biotechs
    26 Feb 2014, 08:57 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs